300558 贝达药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.5715.0187.4386.8923.091
总资产报酬率 ROA (%)2.8963.0684.3554.0812.051
投入资产回报率 ROIC (%)3.2633.5285.1114.8282.452

边际利润分析
销售毛利率 (%)76.43579.53581.37983.53288.694
营业利润率 (%)18.68111.59213.82710.9953.989
息税前利润/营业总收入 (%)21.39513.86314.87514.72411.072
净利润/营业总收入 (%)14.8137.93013.38113.5835.250

收益指标分析
经营活动净收益/利润总额(%)88.269108.856109.48675.225-22.028
价值变动净收益/利润总额(%)12.296-19.144-10.394-4.244-23.545
营业外收支净额/利润总额(%)-0.218-0.970-1.45016.147-8.251

偿债能力分析
流动比率 (X)0.8470.8230.6630.8460.823
速动比率 (X)0.6710.6240.5060.6650.646
资产负债率 (%)35.56336.89339.34641.49437.325
带息债务/全部投入资本 (%)24.45923.96427.19429.68724.748
股东权益/带息债务 (%)293.010296.725255.086229.159292.509
股东权益/负债合计 (%)180.898169.195151.645138.352164.239
利息保障倍数 (X)7.7675.81811.9409.1361.499

营运能力分析
应收账款周转天数 (天)44.46222.42823.95552.74445.613
存货周转天数 (天)143.902163.571206.428311.364445.819